By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ViiV Healthcare 

Five Moore Drive

Research Triangle Park  North Carolina  27709-3398  U.S.A.
Phone: 877-844-8872 Fax: n/a


Company News
ViiV Healthcare Begins Phase III Programme With dolutegravir/rilpivirine Combination For HIV Maintenance Therapy 5/6/2015 6:25:33 AM
ViiV Healthcare Launches New Global Positive Action Program Focused On MSM & Transgender Population 3/31/2015 2:06:37 PM
ViiV Healthcare Wins for Corporate Reputation With Patients While Gilead (GILD) Freefalls Down List 2/16/2015 6:20:44 AM
ViiV Healthcare Announces $10 Million Initiative To Accelerate Response To HIV/AIDS Among Black Gay And Bisexual Men 2/4/2015 8:58:36 AM
Mylan Inc. (MYL) Receives Tentative FDA Approval For Pediatric Formulations Of abacavir/lamivudine Through Innovative Collaboration With ViiV Healthcare And Clinton Health Access Initiative 12/4/2014 12:02:58 PM
ViiV Healthcare Expands Program To Reduce HIV Disparities In Southern U.S. 10/20/2014 8:47:30 AM
ViiV Healthcare Receives Approval For Triumeqâ„¢ (dolutegravir/abacavir/lamivudine), In Canada - A New Once-Daily Single-Pill Regimen For The Treatment Of HIV 10/14/2014 2:14:21 PM
GlaxoSmithKline (GSK)-Pfizer Inc. (PFE)'s ViiV Healthcare Wins Approval For HIV Combo Drug 8/22/2014 4:16:49 PM
ViiV Healthcare: HIV Combo Therapy Candidate Fails Phase 3 7/22/2014 11:58:34 AM
GlaxoSmithKline (GSK)'s ViiV Healthcare Joins Johnson & Johnson (JNJ)'s Janssen Research & Development To Develop Single-Pill HIV Drug 6/12/2014 6:50:49 AM